Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 4/20 | 0.42 |
| ▸ | CCR5 | P51681 | 4/20 | 0.42 |
| ▸ | CCR8 | P51685 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | METAP1 | P53582 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caerulomycin F SCHEMBL29884857 | 0.85 | HSP90AA1 (0.58) | HSP90AA1FFAR1CRHR1NPC1RAB9A | |
| SCHEMBL197885 | 0.84 | HSP90AA1 (0.66) | HSP90AA1FFAR1CRHR1NPC1RAB9A | |
| SCHEMBL7771784 | 0.79 | HSP90AA1 (0.45) | HSP90AA1FFAR1NPC1RAB9ACCR1 | |
| SCHEMBL8515531 | 0.79 | LYN (0.42) | LMNAL3MBTL1KDM4ECYP1A2POLB | |
| SCHEMBL4735238 | 0.78 | HSP90AA1 (0.59) | HSP90AA1FFAR1CRHR1NPC1RAB9A | |
| SCHEMBL8515849 | 0.78 | HSP90AA1 (0.47) | HSP90AA1FFAR1SMN1; SMN2LMNAGAA | |
| SCHEMBL3666895 | 0.78 | NPC1 (0.47) | FFAR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14615313 | 0.77 | HSP90AA1 (0.58) | HSP90AA1FFAR1CRHR1NPC1RAB9A | |
| SCHEMBL1366769 | 0.77 | HSP90AA1 (0.58) | HSP90AA1FFAR1CRHR1NPC1RAB9A | |
| SCHEMBL17850518 | 0.76 | KAT6A (0.43) | HSP90AA1FFAR1CRHR1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-20140005195-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| EP-2643299-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | Noscira, S.A. (ES) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069428-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069428-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005195-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | SNCA, PSEN2, PSEN1 | HSP90AA1 215/4885FFAR1 2038/4885CRHR1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.